Objectives: The emerging fungal pathogens comprising the Candida haemulonii complex (Candida haemulonii, Candida haemulonii var. vulnera and Candida duobushaemulonii) are notable for their antifungal resistance. Twelve isolates with phenotypic similarity to C. haemulonii were recovered from patients in Brazilian hospitals. Here we aimed to identify these isolates by a molecular approach, using the current classification of this fungal complex, and to evaluate their antifungal susceptibility profiles.
Introduction
Candida haemulonii has emerged as an opportunistic fungal pathogen associated with onychomycosis, 1 vaginal candidiasis, 2 bloodstream infections, 3 -5 catheter-related fungemia, 6 osteitis 7 and outbreaks in neonatal intensive care units. 8 Although regarded as a rare Candida species, it deserves attention because it is considered a multidrug-resistant yeast, 5, 8, 9 with clinical failure associated with resistance to amphotericin B and reduced susceptibility to azoles, resulting in difficulty in treating deep infections. 3, 10, 11 The first isolation of C. haemulonii from humans was reported in 1984, from the blood of a patient who died of renal failure despite therapy with amphotericin B and flucytosine. 12 Since then, several cases of infection due to this yeast have been described in the literature, varying from superficial to deep infections. Cendejas-Bueno et al. 9 suggested the reclassification of C. haemulonii as a fungal complex formed by three genotypically distinguishable species: C. haemulonii, Candida duobushaemulonii and C. haemulonii var. vulnera, based on sequencing of D1/D2 or ITS genes. Moreover, two species related to C. haemulonii complex were described, Candida pseudohaemulonii 13 and Candida auris, 14 which are responsible for fungaemia and also present antifungal resistance profiles. Despite the importance of these emergent multiresistant yeasts, little information on the occurrence and distribution of C. haemulonii complex in clinical specimens has been available until now. With this in mind, we obtained 12 strains of C. haemulonii isolated from Brazilian hospitals and performed molecular identification based on ITS gene sequencing to correctly classify them within the current taxonomy of this fungal complex. In parallel, we evaluated the antifungal susceptibility profile of these clinical isolates against amphotericin B, fluconazole, itraconazole, voriconazole and caspofungin.
Materials and methods

Microorganisms, growth conditions and biochemical identification
In this study, we analysed 12 clinical isolates of C. haemulonii recovered from 12 patients attending four Brazilian hospitals between 2005 and 2013 (Table 1) . Fungal isolates were grown on Sabouraud dextrose medium (378C/48 h/200 rpm) and then phenotypically identified using CHROMagar Candida w (CHROMagar Company) and VITEK w 2 (bioMérieux) with YST card.
DNA extraction, amplification and nucleotide sequence determination
Yeasts were recovered from Sabouraud dextrose agar and used for DNA extraction with the Gentra w Puregene w Yeast and G+ Bacteria Kit (Qiagen w ). All isolates were identified by sequencing the ITS1-5.8S-ITS2 gene as previously described. 9, 10 Amplicons were purified and sequences from both DNA strands were generated and edited with the Sequencher TM version 4.9 (Gene Codes Corporation), followed by alignment using Mega version 4.0.2 software.
Antifungal susceptibility assay
Susceptibility testing was performed according to the standardized broth microdilution technique described by CLSI 15 in document M27-A3 and interpreted according to document M27-S3. Antifungals tested were amphotericin B, fluconazole, itraconazole, voriconazole and caspofungin (Sigma-Aldrich).
Results and discussion
The fungal isolates were initially reconfirmed to certify their authentication by mycology methodologies. All isolates developed a light-to-dark violet colour after 48 h of incubation on CHROMagar Candida w ; however, other Candida species (e.g. C. glabrata) also develop violet pigmentation in this chromogenic medium. 16 The carbohydrate assimilation and metabolic enzymatic profiles evaluated with VITEK w 2 identified all 12 Brazilian clinical isolates as C. haemulonii with a probability of identity ranging from 94 to 98%; only two contradictory tests were detected: glycerol assimilation (2/12 isolates, 16.7%) and a-glucosidase (4/12 isolates, 33.3%) ( Table 1) .
Phenotypic methods are not sufficient to differentiate species of the C. haemulonii complex and the closely related species C. pseudohaemulonii and C. auris; 3,9,10 consequently, molecular The MIC values are shown in Table S1 .
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identification was carried out. PCR followed by sequencing of the ITS gene was used as the gold standard for identification of this fungal complex. 9 Our results revealed that among the 12 clinical isolates, five were identified as C. haemulonii (41.7%), four as C. duobushaemulonii (33.3%) and three as C. haemulonii var. vulnera (25%) ( Table 1 ). The ITS sequencing alignment scores of the fungal isolates employed here exhibited 100% identity compared with corresponding ITS sequences from reference isolates deposited in GenBank (Figure 1 ). The ITS sequences obtained during this study were deposited in GenBank under the accession numbers listed in Table 1 .
To our knowledge, this is the first report of the identification of the three species of C. haemulonii complex in clinical isolates from patients attending Brazilian hospitals. It is noteworthy that the isolate LIP Ch8 was previously described as C. haemulonii, 4 also based on ITS gene sequencing; however, that study was conducted before the aforementioned reclassification of the C. haemulonii complex. 9 Our data reallocated the isolate LIP Ch8 as C. duobushaemulonii. Additionally, C. haemulonii, C. haemulonii var. vulnera and C. duobushaemulonii were identified in both cutaneous and blood samples from Brazilian patients ( Table 1) . Species of C. haemulonii complex had already been isolated from distinct environments, including the gut of Haemulon sciurus (fish), Pyrrhocoris apterus (insect) and human nails, skin, blood, bone, respiratory specimens and urine. 7, 9, 11 Concerning the antifungal susceptibility tests, all 12 isolates of the C. haemulonii complex were considered resistant to amphotericin B (MICs ranged from 2 to .16 mg/L) and fluconazole (MICs ≥64 mg/L) ( Table 1 and Table S1 , available as Supplementary data at JAC Online). One isolate of C. haemulonii var. vulnera and two isolates of C. duobushaemulonii were susceptible-dose dependent to itraconazole, while the remaining isolates were resistant to this antifungal agent (Tables 1 and S1 ). Four fungal isolates (C. haemulonii LIP Ch2, C. haemulonii var. vulnera LIP Ch5 and C. duobushaemulonii LIP Ch6 and LIP Ch10) were susceptible to voriconazole with MIC values ≤1 mg/L, while the others were resistant with MIC values ≥16 mg/L. In addition, all the fungal isolates were susceptible to caspofungin (Tables 1 and S1) .
Results from the ARTEMIS DISK Global Antifungal Surveillance Study (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) showed that infections caused by C. haemulonii were very infrequent (,0.01%), and at that time 11.1% of these isolates were resistant to fluconazole and itraconazole. 17 A retrospective study 18 showed that, of the species responsible for causing candidaemia, C. haemulonii was the sixth most common (1.5%) in an Indian hospital between 2001 and 2005, but no true antifungal resistance was reported. C. haemulonii Figure 1 . Phylogenetic neighbour-joining dendrogram generated from a genetic similarity matrix based on comparison of the ITS1-5.8S-ITS2 gene sequence from 12 clinical isolates obtained in the present work (LIP Ch1 to LIP Ch12), as well as 13 sequences of isolates belonging to the C. haemulonii complex and two closely related species (C. auris and C. pseudohaemulonii) obtained from the GenBank database. Data consistency was tested by bootstrapping the alignments 1000 times with corrections for multiple substitutions.
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Candida haemulonii complex in clinical isolates from Brazil was the fourth most common species of Candida isolated from individuals with cutaneous candidiasis (12% of the total) attending the Human and Veterinary Diagnostic Mycology Sector of UFF (Niteró i, RJ, Brazil). 19 The emergence of C. haemulonii in five Korean hospitals was reported between 2004 and 2006, with genotyping results suggesting intra-and inter-hospital transmission of a clonal strain. 10 C. haemulonii was the third most frequent species responsible for causing candidaemia in Sir Ganga Ram Hospital (New Delhi, India), representing 15.5% of the cases, following Candida tropicalis (29.2%) and C. albicans (16.8%). 5 Impressively, the authors reported that C. haemulonii was first isolated in 2006 and its frequency of isolation increased from 5.45% in 2006 to 18.2% in 2008, showing resistance to amphotericin B and azoles. 5 Interestingly, the authors also analysed the annual usage of antifungal drugs between 2000 and 2008, and observed an increase of 32% in total antifungal use. 5 According to this analysis, fluconazole was the most frequently prescribed antifungal drug in the mentioned period, with an increase of 25% in its use, and a statistically significant correlation was observed between yearly fluconazole usage and the increase in isolation of different non-albicans Candida species. 5 Antifungal resistance is a great concern in the management of patients with invasive candidiasis. 20 In vitro resistance to amphotericin B and fluconazole is a common phenotypic characteristic of clinical isolates of the C. haemulonii complex already described by several authors, and it has often been associated with clinical treatment failure and fatal outcome. 5,8 -11 Concerning the use of itraconazole, some authors have reported variable patterns of susceptibility of the C. haemulonii complex to this antifungal. 3, 5, 8, 10 In disagreement with the published literature, the majority (≈67%) of the isolates of the C. haemulonii complex studied here were resistant to voriconazole.
Cendejas-Bueno et al. 9 observed a subtle difference in azole MICs among the species of the C. haemulonii complex, in which C. haemulonii showed higher MICs than the others, especially of itraconazole and voriconazole. In this regard, we demonstrated that 100% and 80% of C. haemulonii isolates were resistant to itraconazole and voriconazole, respectively, while 50% of C. duobushaemulonii and 33.3% of C. haemulonii var. vulnera were resistant to both antifungal agents. It is remarkable that three out of four isolates (75%) dose-dependently susceptible to itraconazole were also susceptible to voriconazole. Although echinocandins are highly active against C. haemulonii complex, 3, 10 isolates resistant to this antifungal class have been reported. 6, 9 During recent decades, there has been a change in the epidemiology of Candida infections, characterized by a progressive shift from a predominance of C. albicans to non-albicans Candida species. 20 As a consequence, new Candida species have appeared and been recognized as potential pathogens, being described as emerging fungi, some of them innately resistant to commonly used antifungal drugs. 20 Therefore, rapid and correct identification of Candida species has become more important in deciding the appropriate starting treatment and providing optimal management of infections. 20 Overall, our results reinforce the importance of molecular identification in differentiating the species comprising the C. haemulonii complex. To date, very little is known regarding the clinical characteristics and antifungal susceptibility profiles of clinical isolates of the C. haemulonii complex. Clinical experience with C. haemulonii complex infection is extremely limited; consequently, no treatment regimen for invasive infections caused by these fungi has been clearly established. Antifungal susceptibility is a particularly relevant problem in managing invasive C. haemulonii complex infection due to its multidrug resistance profile, which represents a future therapeutic challenge to clinicians. Finally, continued surveillance regarding non-albicans Candida species, such as species of the C. haemulonii complex, both locally and on a regional and international basis, is clearly warranted.
